Possible prevention of tuberous sclerosis complex lesions

Area of Science:

• Genetics
• Oncology
• Pharmacology

Background:

• Tuberous Sclerosis Complex (TSC) is a genetic disorder characterized by mammalian target of rapamycin (mTOR) pathway hyperactivation.
• TSC leads to the development of benign tumors (lesions) in various organs, including the brain, kidneys, and skin.
• Everolimus, an mTOR inhibitor, has shown efficacy in treating existing TSC-related tumors like subependymal giant cell astrocytomas and renal angiomyolipomas.

Observation:

• A case study involving monozygotic twin sisters with TSC was conducted.
• One twin received early treatment with everolimus starting at age 4, while the other received no mTOR inhibitor therapy.
• Both twins were followed for a 24-month period.

Findings:

• The twin treated with everolimus experienced a significant reduction in brain tumor volume.
• The treated twin did not develop facial angiofibromas or renal angiomyolipomas.
• The untreated twin's brain tumor remained stable, but she developed significant facial angiofibromas and renal angiomyolipomas.

Implications:

• Early initiation of mTOR inhibition in TSC patients may prevent the formation of new TSC lesions.
• This approach could potentially modify the natural course of Tuberous Sclerosis Complex.
• Findings support the role of mTOR signaling in TSC pathogenesis and suggest therapeutic targets for lesion prevention.